All relevant data are within the paper and its Supporting Information files.

Background {#sec005}
==========

Adverse drug reactions (ADRs) contribute to the global burden of ill-health\[[@pone.0123974.ref001]--[@pone.0123974.ref003]\]. Efficient ADR detection and reporting systems in sub-Saharan Africa (SSA) could promote more effective management of medicines and foster improvements in the quality of healthcare\[[@pone.0123974.ref004]\]. The detection or suspicion of ADRs by healthcare professionals (HCPs) is a first step in ADR reporting\[[@pone.0123974.ref005]\]. The ability of HCPs to suspect or recognize ADRs and ably to differentiate them from patients' illnesses and/or to attribute them across co-administered medications are, however, major challenges\[[@pone.0123974.ref006]\]. Ugandan HCPs involved in medical research and non-nurses were more likely to have suspected an ADR in the previous month, but previous-month receipt of a patient ADR complaint was the dominant factor in triggering ADR suspicion\[[@pone.0123974.ref005]\].

The spontaneous suspected ADR reporting system in Uganda currently requires completion, by HCPs, of a paper-based ADR report form, see [S1 Appendix](#pone.0123974.s001){ref-type="supplementary-material"} for details. Only a small proportion (13%) of previous-month suspected ADRs that surveyed Ugandan HCPs detected in routine clinical practice were reported\[[@pone.0123974.ref005]\], consistent with ADR under-reporting elsewhere\[[@pone.0123974.ref007]\]. National statistics for voluntary ADR reporting to the Ugandan National Pharmacovigilance Centre (NPC) indicate that only 0.44% of HCPs report suspected ADRs annually\[[@pone.0123974.ref005]\].

Lack of adequate detail in the majority (80%) of suspected ADR reports submitted to the NPC\[[@pone.0123974.ref008]\] is an additional challenge. 'Completeness', as defined by Uppsala Monitoring Centre (UMC)\[[@pone.0123974.ref009]\], is a country-level quantitative measure of how complete is the information on 12 key details, see [S2 Appendix](#pone.0123974.s002){ref-type="supplementary-material"}, in Individual Case Safety Reports (ICSRs) that UMC receives from NPCs. We defined a HCP-level comprehensive ADR description as having at least four of the following five higher-level descriptors: body site, drug class, route of administration, patient's age, and ADR severity. Since we were testing the ability of HCPs to provide focal "free text" ADR descriptions, our target was to identify descriptions with, at most, one missing higher-level descriptor. Except for patient age, none of the other four basic descriptors is explicitly an ICSR key detail. Our higher-level descriptors could be the starting point for the completeness evaluation process by which NPCs elicit UMC's 12 key details, which include the information ideally needed to assess the causality of suspected ADRs: temporal relationship to drug intake, response to drug withdrawal, event or laboratory test abnormality, presence/absence of disease process or other drugs that can explain the ADR, and re-challenge if possible\[[@pone.0123974.ref010]\]. The large proportion of reports with inadequate detail, as submitted to the NPC, poses a challenge for signal detection and causality assessment of suspected ADRs: underestimation of the true risks of patients' medications is the result\[[@pone.0123974.ref011]\]. This study is focused on basic ADR description; we do not address ADR causality.

Ugandan HCPs are encouraged to submit comprehensive reports on suspected ADRs internally within the healthcare system and, ultimately, these reports ought to reach the NPC. Such submissions promote informed risk-benefit evaluation of medications and improve overall patient safety. We investigated how comprehensively Ugandan HCPs described their most recent previous-month suspected ADR, and determined the characteristics of HCPs who provided comprehensive ADR descriptions. We also identified rare, serious, and unanticipated suspected ADR descriptions with medication safety alerting potential.

Methods {#sec006}
=======

Study design and sampling procedure {#sec007}
-----------------------------------

From 25 May 2012 to 28 February 2013, we conducted a cross-sectional study in Uganda in purposively selected, geographically diverse public and private health facilities. Details of the survey-design, anonymous self-completion of survey questionnaire, and sampling procedures have been described elsewhere\[[@pone.0123974.ref005]\]. Briefly, health facilities were selected to include the national referral hospital, and six regional referral hospitals which were selected to be representative of the Central, Eastern, Northern, Southern, and Western regions of Uganda. For practical purposes, district hospitals, health centres II to IV, and private health facilities (both for-profit and not-for-profit) in the catchment areas of the regional referral hospitals were conveniently selected. Healthcare professionals involved in prescribing, transcribing, dispensing medication orders, and administration of medicines to patients in the selected health facilities were eligible. Pre-trained research assistants approached HCPs and invited them to complete a pretested self-administered questionnaire. Healthcare professionals who accepted to participate gave separately-held written informed consent\[[@pone.0123974.ref005]\]. The self-completed questionnaires were tracked using serial numbers and they did not elicit identifying information on individual HCPs\[[@pone.0123974.ref005]\]. Two-thirds of the issued questionnaires were returned.

Data collection and management {#sec008}
------------------------------

The self-administered questionnaire was used to obtain demographic and professional information; and description of the most recent previous-month suspected ADR\[[@pone.0123974.ref005]\], see [S3 Appendix](#pone.0123974.s003){ref-type="supplementary-material"}. Descriptions of the most recent suspected ADR were rated on the presence/absence of five higher-level descriptors: body site, drug class, route of administration, patient's age, and ADR severity. Comprehensiveness of ADR description was defined by the presence of at least four descriptors.

We distinguished between a severe suspected ADR and a serious suspected ADR. A serious ADR is one that can result in death, is life-threatening, requires initial or prolonged hospitalization, or results in disability or incapacitation\[[@pone.0123974.ref012]\]. Severity of an ADR describes its intensity as: mild, moderate or severe\[[@pone.0123974.ref013]\]. Thus, a severe ADR (severity grade 3) is not synonymous with a serious ADR\[[@pone.0123974.ref013]\].

We defined rare ADRs as those which are reported to occur less often than in10 per 10,000 individuals on specified medication (≤ 0.1%)\[[@pone.0123974.ref014]\]; and unanticipated ADRs as those which, to our knowledge, are not supported by existing literature.

When invited to describe their most recent previous-month suspected ADR, some HCPs provided descriptions for two to three such cases. We used simple random sampling to retain one ADR description from each such set for analysis, see [S4 Appendix](#pone.0123974.s004){ref-type="supplementary-material"}.

All data were entered into a databank using EpiData 3.1.

Analysis {#sec009}
--------

Free-text descriptions for all ADRs and how we coded them for the five higher-level descriptors are provided in the [S5 Appendix](#pone.0123974.s005){ref-type="supplementary-material"}. Severity of ADRs, as reported by HCPs, was not altered by the study investigators in subsequent analyses.

Two investigators (RK & SMB) each independently assessed the comprehensiveness of the 241 ADR descriptions: disagreements were resolved by consensus, and the consensus judgement on the five higher-level descriptors is provided in the [S5 Appendix](#pone.0123974.s005){ref-type="supplementary-material"}.

Seriousness of ADRs was assessed by RK based on the definition by the WHO Uppsala Monitoring Centre (UMC) classification\[[@pone.0123974.ref012]\] while the assessment of rareness and unanticipated ADR was conducted by RK using the online British National Formulary as the key reference guide\[[@pone.0123974.ref015]\].

Questionnaire responses and higher-level ADR descriptors were summarized as frequencies and percentages. We used logistic regression to assess demographic and professional determinants of comprehensiveness in describing the most recent of past-month suspected ADRs. Regression coefficients were expressed as odds ratios (ORs) with 95% confidence intervals and were obtained using Stata 12.0\[[@pone.0123974.ref016]\]. We accounted for missing data using the missing-assigned approach where low-frequency missing data were meaningfully assigned to an existing category.

Descriptions of serious (incapacitating or life-threatening) suspected ADRs were tabulated by drug class, see [S6 Appendix](#pone.0123974.s006){ref-type="supplementary-material"}; and for similar listing of severe (grade 3 intensity) suspected ADRs, see [S7 Appendix](#pone.0123974.s007){ref-type="supplementary-material"}. For ease of assimilation, rare suspected ADRs were grouped by whether or not SJS was explicitly mentioned; if not, rare ADRs were listed by the named drug.

Ethical clearance {#sec010}
-----------------

The School of Medicine Research and Ethics Committee, Makerere University College of Health Sciences, and the Uganda National Council for Science and Technology provided ethical approval for the study.

Results {#sec011}
=======

Study population {#sec012}
----------------

Overall return-rate for the survey was 67% (1,345/2,000) and the mean number of patients seen per day by HCPs was 41 \[(SD = 46), median of 30 (interquartile range from 15 to 50 patients/day; n = 1,226 of 1,345)\]. Only 21% (268/1,289) of HCPs reported that they had suspected an ADR in the previous month. The mean age of respondent HCPs who suspected an ADR in the previous 4-weeks was 32.2 years (SD = 8.5; n = 222 of 268). Twenty seven (10%) of the 268 HCPs who suspected an ADR in the previous month did not provide any ADR description. Of the 241 who did, 95 (39%) were nurses, 77 (32%) were doctors, 23 (10%) were pharmacists/pharmacy technicians and 46 (19%) were other cadres.

Suspected ADRs {#sec013}
--------------

Of the 268 HCPs who had suspected an ADR in the previous month, 241 (90%) provided a free-text description of the most recently encountered previous-month suspected ADR with higher-level details given as follows: *body-site* \[85%, 206/241; skin only reactions were the modal group (43%, 88/206)\]; *drug class* \[84%, 203/241; with the top three single classes cited as follows: antibacterials (70), antiretrovirals (45), and antimalarials (28)\]; *route of administration* \[(explicitly cited: 53%, 127/241), although, in addition, route could be inferred from the named-drug in a further 63 descriptions (hence, 79%); with 50 of 190 being by injection\]; *patient's age* \[55%, 133/241; mean age 28.3 years (SD = 16.5), median of 28 years and inter-quartile range from 20 to 36 years\]; and *ADR-severity* \[53%, 128/241; with 46% (59/128) of citations being in respect of severe reactions\], see [Table 1](#pone.0123974.t001){ref-type="table"} and [S4 Appendix](#pone.0123974.s004){ref-type="supplementary-material"}.

10.1371/journal.pone.0123974.t001

###### Survey-description of the most recent past-month suspected ADR provided by 241 out of 268 HCPs who suspected ADRs in the previous month, Uganda, 2013.
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  --------------------------------------------------------------------- --------------- ------------------ -----------------------------------
  **Body site distribution for 206 suspected ADR descriptions**                                            
  **Body site of ADR**                                                  **Frequency**   **Per cent**        **Per cent-body site reported**
  Skin only                                                             88              37%                43%
  Central Nervous System (CNS) only                                     20              8%                 10%
  Gastrointestinal Tract (GI) only                                      18              7%                 9%
  Skin & CNS                                                            6               3%                 2%
  Skin & GI                                                             4               2%                 2%
  CNS & GI                                                              4               2%                 2%
  Other                                                                 66              27%                32%
  Not reported                                                          35              14%                \-
  **Total**                                                             **241**         **100%**           **100% **
  **Drug class distribution for 203 suspected ADR descriptions**                                           
  **Drug class**                                                        **Frequency**   **Per cent**        **Per cent-drug class reported**
  Antibacterials only                                                   70              29%                34%
  Antiretrovirals only                                                  45              19%                22%
  Antimalarials only                                                    28              12%                14%
  Antibacterials & Antiretrovirals                                      1               0%                 1%
  Antibacterials & Antimalarials                                        4               1%                 2%
  Other                                                                 55              23%                27%
  Not reported                                                          38              16%                \-
  **Total**                                                             **241**         **100%**           **100%** 
  **Route of drug administration for 127 suspected ADR descriptions**                                      
  **Route of administration[\*](#t001fn001){ref-type="table-fn"}**      **Frequency**   **Per cent**        **Per cent-route reported**
  Oral or Topical                                                       83              34%                65%
  Injectable                                                            44              18%                35%
  Not reported                                                          114             47%                \-
  **Total**                                                             **241**         **100%**           **100%** 
  **Patient's age distribution for 133 suspected ADR descriptions**                                        
  **Patient age (n = 133)**                                             **Mean (SD)**   **Median (IQR)**   
  Measure of central tendency                                           28.3 (16.5)     28 (20--36)        
  **ADR Severity distribution for 128 suspected ADR descriptions**                                         
  **Severity of ADR**                                                   **Frequency**   **Per cent**       **Per cent---severity**
  Mild                                                                  27              11%                 21%
  Moderate                                                              42              17%                33% 
  Severe                                                                59              24%                46% 
  Not reported                                                          113             47%                \-
  **Total**                                                             **241**         **100%**           **100%** 
  --------------------------------------------------------------------- --------------- ------------------ -----------------------------------

\*Route of administration could be inferred for a further 63 (6 were by injection & 59 were oral) ADR descriptions.

Comprehensive survey-described suspected ADRs {#sec014}
---------------------------------------------

Comprehensiveness of ADR description was achieved by 46% (124/268; 95% CI: 40% to 52%) of HCPs when only 85 would have been expected by independence of descriptors, see [Table 2](#pone.0123974.t002){ref-type="table"}.

10.1371/journal.pone.0123974.t002

###### Comprehensiveness of ADR-description of the most recent past-month suspected ADR(s) as reported by 241 out of 268 HCPs who suspected ADRs in the previous month, Uganda, 2013.
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  HIGHER-LEVEL DETAILS in addition to ADR   Body Site   Drug Class   Route      Age of patient   Severity   Observed number   Expected by independence
  ----------------------------------------- ----------- ------------ ---------- ---------------- ---------- ----------------- --------------------------
  **All 5 provided**                        **√**       **√**        **√**      **√**            **√**      **54**            **17**
                                            206/268      203/268      127/268    133/268          128/268                     
  **Combinations of 4**                                                                                                       
  Combination 1                             **√**       **√**        **√**      **√**                       22                19
  Combination 2                                         **√**        **√**      **√**            **√**      **10**            **5**
  Combination 3                             **√**       **√**                   **√**            **√**      19                20
  Combination 4                             **√**                    **√**      **√**            **√**      2                 6
  Combination 5                             **√**       **√**        **√**                       **√**      17                18
  **TOTAL**                                 **124**     **85**                                                                

The more comprehensive ADR descriptions were received from HCPs in private health facilities \[vs. public; private not-for-profit (OR = 3.4, 95% CI: 1.48 to 7.82) & private for-profit (OR = 2.6, 95% CI: 1.13--5.96)\], and regions other than Central Uganda \[Eastern (OR = 2.6, 95% CI: 1.20--5.73) & combined Western-Northern-Southern (OR = 6.4, 95% CI: 2.85--14.37)\]. Comprehensive ADR description was less likely from HCPs who were involved in teaching medical students (OR = 0.5, 95% CI: 0.23--1.00) and was not significantly influenced by professional cadre (nurse versus non-nurse), life-time encountering of a fatal ADR, age of HCP, receipt of a previous-month patient ADR complaint, involvement in medical research, patient load, department, and knowing to whom to report ADRs, see [Table 3](#pone.0123974.t003){ref-type="table"}.

10.1371/journal.pone.0123974.t003

###### Personal and professional factors associated with comprehensive ADR description of most recent past-month suspected ADR for 241 healthcare professionals who suspected ADR(s) in the previous month and provided a description, Uganda, 2013.
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  Factor                                                                        Comprehensive ADR Description   Crude Analysis   Adjusted Analysis                                              
  ----------------------------------------------------------------------------- ------------------------------- ---------------- ------------------- ------------ --------- ----- ------------- ---------
  Level of Health Facility                                                                                                                                                                      
    Other                                                                       37 (56)                         29 (44)          1.0                                        1.0                 
    Hospital                                                                    87 (50)                         88 (50)          0.8                 0.44--1.37   0.380     2.0   0.86--4.47    0.110
  Type of Health Facility                                                                                                                                                                       
    Public                                                                      49 (41)                         71 (59)          1.0                                        1.0                 
    Private Not-For-Profit                                                      31 (67)                         15 (33)          3.0                 1.46--6.13   0.003     3.4   1.48--7.82    0.004
    Private For-Profit                                                          44 (59)                         31 (41)          2.1                 1.14--3.70   0.016     2.6   1.13--5.96    0.024
  Region of the country                                                                                                                                                                         
    Central                                                                     49 (37)                         82 (63)          1.0                                        1.0                 
    Eastern                                                                     34 (62)                         21 (38)          2.7                 1.42--5.18   0.003     2.6   1.20--5.73    0.015
    Other                                                                       41 (75)                         14 (25)          4.9                 2.43--9.89   \<0.001   6.4   2.85--14.37   \<0.001
  Professional Cadre                                                                                                                                                                            
    Nurse                                                                       54 (57)                         41 (43)          1.0                                        1.0                 
    Non-nurse                                                                   70 (48)                         76 (52)          0.7                 0.42--1.18   0.178     1.1   0.54--2.32    0.769
  Age                                                                                                                                                                                           
    Less than 30 years                                                          53 (50)                         54 (50)          1.0                                        1.0                 
    Aged 30 years or older                                                      71 (53)                         63 (47)          1.1                 0.69--1.91   0.594     1.7   0.92--3.09    0.090
  Patient Load                                                                                                                                                                                  
    Greater than 30/day                                                         59 (50)                         58 (50)          1.0                                        1.0                 
    At most 30/day                                                              65 (52)                         59 (48)          1.1                 0.65--1.80   0.757     1.4   0.78--2.66    0.241
  Department                                                                                                                                                                                    
    Medicine                                                                    70 (52)                         64 (48)          1.0                                        1.0                 
    Surgery                                                                     4 (31)                          9 (69)           0.4                 0.12--1.38   0.150     0.4   0.09--1.47    0.156
    Paediatrics, OBS & Gyn                                                      16 (43)                         21 (57)          0.7                 0.33--1.45   0.334     0.7   0.29--1.64    0.404
    Other                                                                       34 (60)                         23 (40)          1.4                 0.72--2.53   0.347     1.0   0.48--2.04    0.973
  Teaching medical students                                                                                                                                                                     
    No                                                                          101 (57)                        75 (43)          1.0                                        1.0                 
    Yes                                                                         23 (35)                         42 (65)          0.4                 0.23--0.73   0.003     0.5   0.23--1.00    0.050
  Ever encountered fatal ADR                                                                                                                                                                    
    No                                                                          98 (55)                         79 (45)          1.0                                        1.0                 
    Yes                                                                         26 (41)                         38 (59)          0.6                 0.31--0.99   0.044     0.7   0.35--1.42    0.327
  Involved in medical research                                                                                                                                                                  
    No                                                                          75 (51)                         71 (49)          1.0                                        1.0                 
    Yes                                                                         49 (52)                         46 (48)          1.0                 0.60--1.69   0.975     1.8   0.96--3.43    0.068
  Gender                                                                                                                                                                                        
    Male                                                                        57 (47)                         64 (53)          1.0                                        1.0                 
    Female                                                                      67 (56)                         53 (44)          1.4                 0.85--2.36   0.176     1.4   0.70--2.82    0.334
  Suggestions for improved ADR reporting[\*](#t003fn001){ref-type="table-fn"}                                                                                                                   
    No                                                                          21 (49)                         22 (51)          1.0                                                            
    Yes                                                                         103 (52)                        95 (48)          1.1                 0.59--2.20   0.705                         
  Knows to whom to report[\*](#t003fn001){ref-type="table-fn"}                                                                                                                                  
    No                                                                          51 (45)                         63 (55)          1.0                                                            
    Yes                                                                         73 (58)                         54 (42)          1.7                 1.00--2.78   0.049                         
  Patient ADR complaint[\*](#t003fn001){ref-type="table-fn"}                                                                                                                                    
    No                                                                          35 (55)                         29 (45)          1.0                                                            
    Yes                                                                         89 (50)                         88 (50)          0.8                 0.47--1.49   0.546                         

\* Covariates not fitted into the final logistic regression model.

Serious suspected ADRs {#sec015}
----------------------

Serious suspected ADRs constituted 44% (106/241) of the ADR descriptions; see [S6 Appendix](#pone.0123974.s006){ref-type="supplementary-material"} for list of the 106 serious suspected ADRs. The most frequent body sites of serious ADRs were skin only (33%, 34/102), central nervous system (CNS) only (11%, 11/102), and gastrointestinal tract (GI) only (8%, 8/102), see [Table 4](#pone.0123974.t004){ref-type="table"}. The most frequent *single* drug classes of serious ADRs were antiretrovirals (35%, 31/88), antibacterials (15%, 13/88) and antimalarials (14%, 12/88), see [Table 4](#pone.0123974.t004){ref-type="table"}. Serious suspected ADRs accounted for only 24% (13/53: 95% CI: 13%- 36%) of antibacterial-only-linked ADR descriptions but for 82% (31/38: 95% CI: 70%- 94%) of antiretroviral-only-linked suspected ADR descriptions, and for 46% (12/26: 95% CI: 27%- 65%) of antimalarial-only-linked suspected ADRs \[Chi (2 df) = 29.35; P \< 0.001\]. Severity (grade or intensity) was not reported for half (53/106) of the serious (incapacitating or life-threatening) ADRs.

10.1371/journal.pone.0123974.t004

###### Seriousness of the most recent past-month suspected ADRs described by 241 out of 268 HCPs who suspected ADRs in the previous month, Uganda, 2013.
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  ------------------------------------------------------------------------ ------------------------- -------------------------- --------------- ---------------
  **Serious ADR distribution for 241 suspected ADR descriptions (n, %)**                                                                        
  **Serious ADR**                                                          **Body Site Specified**   **Drug Class Specified**   **Frequency**   
  Yes                                                                      102 (50)                   88 (43)                   106 (44)        
  No                                                                       93 (45)                    84 (41)                   97 (40)         
  Unassessable                                                             11 (5)                     31 (15)                   38 (16)         
  **Total**                                                                **206 (100)**             ** 203 (100)**             **241 (100)**   
  **Serious ADR by Body Site for 206 suspected ADR descriptions**                                                                               
  **Body Site**                                                                                      **Serious ADR (n, %)**                     
  **Yes**                                                                  **No**                    **Unassessable**           **Total**       
  Skin only[\*](#t004fn002){ref-type="table-fn"}                           34 (33)                   47 (51)                    7 (64)          88 (43)
  CNS only[\*](#t004fn002){ref-type="table-fn"}                            11 (11)                   9 (10)                     0 (0)           20 (10)
  GI only[\*](#t004fn002){ref-type="table-fn"}                             8 (8)                     9 (10)                     1 (9)           18 (9)
  Skin & CNS                                                               3 (3)                     3 (3)                      0 (0)           6 (3)
  Skin & GI                                                                1 (1)                     3 (3)                      0 (0)           4 (2)
  CNS & GI                                                                 2 (2)                     2 (2)                      0 (0)           4 (2)
  Other                                                                    43 (42)                   20 (21)                    3 (27)          66 (31)
  **Total**                                                                **102 (100)**             **93 (100)**               **11 (100)**    **206 (100)**
  **Serious ADR by Drug Class for 203 suspected ADR descriptions**                                                                              
  **Drug Class**                                                           **Serious ADR (n, %)**                                               
  **Yes**                                                                  **No**                    **Unassessable**           **Total**       
  Antibacterials only[\*](#t004fn002){ref-type="table-fn"}                 13 (15)                   40 (48)                    17 (55)         70 (34)
  Antiretrovirals only[\*](#t004fn002){ref-type="table-fn"}                31 (35)                   7 (8)                      7 (23)          45 (22)
  Antimalarials only[\*](#t004fn002){ref-type="table-fn"}                  12 (14)                   14 (17)                    2 (6)           28 (14)
  Antibacterial & Antiretroviral                                           0 (0)                     0 (0)                      1 (3)           1 (1)
  Antibacterials & Antimalarials                                           4 (4)                     0 (0)                      0 (0)           4 (2)
  Other                                                                    28 (32)                   23 (27)                    4 (13)          55 (27)
  **Totals**                                                               **88 (100)**              **84 (100)**               **31 (100)**    **203 (100)**
  **Rare ADR**                                                             **Serious ADR (n, %)**                                               
  **Yes**                                                                  **No**                    **Unassessable**           **Total**       
  Yes                                                                      33 (31)                   18 (19)                    0 (0)           51 (21)
  No                                                                       46 (43)                   57 (59)                    6 (16)          109 (45)
  Unknown                                                                  27 (25)                   22 (22)                    32 (84)         81 (34)
  **Total**                                                                **106 (100)**             **97 (100)**               **38 (100)**    **241 (100)**
  ------------------------------------------------------------------------ ------------------------- -------------------------- --------------- ---------------

Chi-square (2 df) = 6.42, P \< 0.025 (if the "unassessable" column is excluded)

\*Proportions of serious ADRs **(across rows)**, and their 95% confidence intervals (95% CI) for a) body site: skin only, **39% (95% CI: 29%- 49%);** CNS only, **55% (95% CI: 33%- 77%);** GI only, **44% (95% CI: 21%- 67%); &** other, **42% (95% CI: 30%- 54%);** and for, b) drug class: antibacterials only, **24% (95% CI: 13%- 36%)**; antimalarials only, **46% (95% CI: 27%- 65%);** antiretrovirals only, **82% (95% CI: 70%- 94%);** & other, **58% (95% CI: 45%- 71%)**

Case reports of serious suspected ADRs {#sec016}
--------------------------------------

A 28-year-old patient received cotrimoxazole tablets and developed black patches on the skin (reported by a 35-year-old female registered midwife in a public health centre IV, Tororo, Eastern Uganda); severe haemoptysis (coughing up of blood) in a patient after two days on oral diclofenac (reported by a 28-year-old male doctor in a private for-profit hospital in Kampala, Central Uganda); and, a 17-year-old receiving intramuscular quinine developed severe post injection paralysis (reported by a 60-year-old female enrolled nurse in a private-not-for-profit hospital in Mbarara district, Southern Uganda), see [S8 Appendix](#pone.0123974.s008){ref-type="supplementary-material"}.

Rare suspected ADRs {#sec017}
-------------------

Fifty one rare suspected ADRs (which occur in ≤ 0.1% of medication users) were reported, of which 65% (33/51) were serious, see Tables [4](#pone.0123974.t004){ref-type="table"} and [5](#pone.0123974.t005){ref-type="table"}. Among the rare ADR descriptions, Stevens-Johnson syndrome (SJS) was explicitly mentioned in 13 of 51 cases and implicated drugs were: antiretroviral therapy \[five of 13 cases were nevirapine-linked, and one was linked to zidovudine-lamivudine post-exposure prophylaxis\]; cotrimoxazole (septrin) \[four\]; ciprofloxacin \[one\]; carbamazepine \[one\]; and no drug mentioned \[one\].

10.1371/journal.pone.0123974.t005

###### Survey-descriptions of 51 rare suspected Adverse Drug Reactions (ADRs) of Healthcare Professionals (HCPs) who suspected ADRs in the past 4 weeks.
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  Level/Facility                                   Type/Facility       district   Region     Cadre    Nurse-cadre                HCP-Gender   HCP-Age   Rare ADR Description                                                                                                                                                                                                                                                                 Source
  ------------------------------------------------ ------------------- ---------- ---------- -------- -------------------------- ------------ --------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **SJS Explicitly Mentioned**                                                                                                                                                                                                                                                                                                                                                                                                               
  Public                                           Private Hospital    KAMPALA    Central    Doctor                              Male         26        24YR/FEMALE KNOWN IMMUNOSUPPRESSED SYNDROME (ISS) PATIENT ON ANTI-TBS WHO REACTED TO COTRIMOXAZOLE---SJS & ALSO HAD TOXOPLASMOSIS                                                                                                                                                    Cotrimoxazole; \< 1 in 10,000---NHS, BNF
  Private For-Profit                               Private Hospital    TORORO     Eastern    Doctor                              Female       28        A MAN DIAGNOSED WITH HIV TOOK COTRIMOXAZOLE AND GOT STEVENS-JOHNSON SYNDROME SEVERE                                                                                                                                                                                                  Cotrimoxazole; \< 1 in 10,000---NHS, BNF
  Private Not-for-Profit                           District Hospital   MASINDI    Western    Nurse    Registered Nurse Midwife   Female       43        40YRS,SEPTRIN,ORALLY.SJS                                                                                                                                                                                                                                                             Cotrimoxazole; \< 1 in 10,000---NHS, BNF
  Private Not-for-Profit                           Private Hospital    TORORO     Eastern    Other                               Female       25        38YR/MALE ON SEPTRIN DEVELOPED SJS---MODERATE                                                                                                                                                                                                                                        Cotrimoxazole; \< 1 in 10,000---NHS, BNF
  Private For-Profit                               National Referral   KAMPALA    Central    Doctor                              Female       32        36YR MALE ADMITTED WITH SJS FOLLOWING INITIATION OF ORAL NEVIRAPINE,SEVERE EVENT[\*](#t005fn002){ref-type="table-fn"}                                                                                                                                                                NVP; 0.1--0.3%---ehealthme (1 per 1000),Mittmann et al 2012 (1--2 per 1000)
  Private For-Profit                               Health Centre III   MASAKA     Southern   Other                               Female       27        32YR OLD REACTED TO ORAL NEVIRAPINE---SJS. REACTION WAS MODERATE                                                                                                                                                                                                                     NVP; 0.1--0.3%---ehealthme (1 per 1000), Mittmann et al 2012 (1--2 per 1000)
  Private For-Profit                               Private Hospital    WAKISO     Central    Doctor                              Male         27        HIV+/FEMALE NEWLY ENROLLED ON HAART WITH NVP-BASED REGIMEN DEVELOPED SJS WHICH WAS SEVERE                                                                                                                                                                                            NVP; 0.1--0.3%---ehealthme (1 per 1000), Mittmann et al 2012 (1--2 per 1000)
  Private Not-for-Profit                           District Hospital   KAMPALA    Central    Doctor                              Female       33        28YR FEMALE ON ORAL DUOVIR-N (AZT/3TC/NVP), GOT RASH WHICH WORSENED & SHE DEVELOPED SJS                                                                                                                                                                                              BNF
  Public                                           District Hospital   TORORO     Eastern    Nurse    Registered Nurse           Female       48        32YR/FEMALE ISS PATIENT ON AZT/3TC/NVP FOR 3 MONTHS GOT SKIN RASH ALL OVER THE BODY---STEVEN JOHNSON SYNDROME---SEVERE                                                                                                                                                               BNF
  Public                                           Regional Referral   GULU       Northern   Pharm                               Female       26        22YR/FEMALE LADY NURSE WHO GOT NEEDLE STICK INJURY & WAS INITIATED ON PEP WITH AZT/3TC-12 DAYS LATER GOT SEVERE RASH (SJS) & WAS ADMITED AND TREATED                                                                                                                                 [Drugs.com](http://Drugs.com): Database powered by Wolters Kluwer Health, American Society of Health- System Pharmacists, Cerner Multum and Thomson Reuters Micromedex. Not in BNF.
  Public                                           Health Centre III   JINJA      Eastern    Pharm                               Female       26        25YR OLD FEMALE ON CIPROFLOXACIN IV. GOT SJS.IT WAS SEVERE                                                                                                                                                                                                                           BNF
  Private For-Profit                               National Referral   KAMPALA    Central    Doctor                              Female       25        SJS SECONDARY TO CARBAMAZEPINE                                                                                                                                                                                                                                                       BNF
  Private Not-for-Profit                           National Referral   KAMPALA    Central    Nurse    Registered Nurse           Female       27        SJS, MUCOSITIS (WHERE PATIENT CANNOT PUT ANYTHING IN THE MOUTH), DROP IN BLOOD COUNTS                                                                                                                                                                                                No drug stated but SJS known to be a rare ADR
  **Co-trimoxazole (Septrin)---Other Reactions**                                                                                                                                                                                                                                                                                                                                                                                             
  Private Not-for-Profit                           Health Centre IV    BUIKWE     Central    Nurse    Enrolled Comprehensive     Male         25        58YR OLD ON ORAL COTRIMOXAZOLE GOT SEVERE URTICARIA AND SKIN RASHES ALL OVER THE BODY                                                                                                                                                                                                BNF
  Public                                           Health Centre III   GULU       Northern   Other                               Male         26        32YR/FEMALE KNOWN ISS PATIENT ON COTRIMOXAZOLE CAME WITH SEVERE BODY RASHES & SLOUGHING[\*](#t005fn002){ref-type="table-fn"}                                                                                                                                                         BNF
  Private For-Profit                               National Referral   KAMPALA    Central    Other                               Male         32        62YR/FEMALE ON COTRIMOXAZOLE ORAL ROUTE WITHIN TWO DAYS GOT MULTIPLE SKIN PATCHES, DEVELOPED SORES ON MUCOUS MEMBRANES WITH HIGH TEMPERATURE. GIVEN STEROIDS & SHE RECOVERED                                                                                                         BNF
  Public                                           Health Centre III   MITOOMA    Western    Other                               Male         27        HIV+ PATIENT WITH BODY ACHES, SUDDEN SKIN RASH, BURNT SKIN, OOZING OF SWEAT-LIKE FLUID AFTER COTRIMOXAZOLE ADMINISTRATION---MILD SYMPTOMS                                                                                                                                            BNF
  Private For-Profit                               Health Centre IV    TORORO     Eastern    Nurse    Registered Midwife         Female       35        28YR OLD PATIENT WAS ADMINISTERED WITH COTRIMOXAZOLE TABLETS DEVELOPED BLACK PATCHES ON SKIN---MODERATE                                                                                                                                                                              BNF
  Private For-Profit                               Other               KAMPALA    Central    Nurse    Registered Nurse           Male         33        42YR/FEMALE SERO-POSITIVE, NAIVE TO HAART WITH MILD ITCHY RASH, APPETITE LOSS, RISE IN BODY TEMPERATURE & ITCHING WHICH INTENSIFIED ON SWALLOWING SEPTRIN TABLETS FIVE WEEKS AGO. PATIENT RETURNED TO FACILITY & LAB INVESTIGATIONS SHOWED DERRANGED LIVER FUNCTION TEST VARIABLES   BNF
  Public                                           Drug Shop           KAMULI     Eastern    Nurse    Enrolled Nurse             Female       28        OLD WOMAN REACTED TO SEPTRIN,GENERALIZED BODY SORES,GAVE HER PREDISOLONE & PAIN KILLER PLUS BETADERM TOPICAL (BETAMETHASONE)                                                                                                                                                         BNF
  Public                                           Health Centre III   JINJA      Eastern    Nurse    Enrolled Nurse             Female       20        26YR/MALE HIV+ ON ORAL SEPTRIN,GOT BURNT FACE & LIPS-GIVEN ORALDEXAMETHASONE FOR FIVE DAYS---SEVERE                                                                                                                                                                                  BNF
  Public                                           District Hospital   TORORO     Eastern    Nurse    Nursing Assistant          Female       50        A 20YR OLD TAKING SEPTRIN ORALLY GOT SEVERE SKIN RASH ALL OVER THE BODY                                                                                                                                                                                                              BNF
  **Quinine only**                                                                                                                                                                                                                                                                                                                                                                                                                           
  Public                                           Health Centre III   KAMPALA    Central    Other                               Male         32        28YR/FEMALE GOT BODY ITCHING AFTER TAKING ORAL QUININE. ADR WAS MODERATE                                                                                                                                                                                                             Itching = Pruritus; [Drugs.com](http://Drugs.com)
  Private For-Profit                               Drug Shop           KAMULI     Eastern    Nurse    Nursing Assistant          Male         40        55YR OLD MALE ON QUININE TABS ORAL ROUTE GOT BODY ITCHING                                                                                                                                                                                                                            Itching = Pruritus; [Drugs.com](http://Drugs.com)
  Private For-Profit                               Pharmacy            JINJA      Eastern    Pharm                               Female       35        PATIENT REACTED TO QUININE WITH ITCHING, TREATED IT WITH CETIRIZINE                                                                                                                                                                                                                  Itching = Pruritus; [Drugs.com](http://Drugs.com)
  Public                                           Drug Shop           JINJA      Eastern    Nurse    Registered Midwife         Male         30        28YR OLD FEMALE REACTED TO QUININE IV LEADING TO MISCARRIAGE                                                                                                                                                                                                                         Manufacturer\'s information leaflet: [Drugs.com](http://Drugs.com)
  Public                                           Private Hospital    MBRA       Southern   Nurse    Enrolled Nurse             Female       50        PATIENT ON ORAL QNN GOT SKIN RASH,TINNITUS,ABORTION,VERTIGO, NAUSEA, VOMITING, BLURRED VISION---SEVERE                                                                                                                                                                               Manufacturer\'s information leaflet-miscarriage = abortion: [Drugs.com](http://Drugs.com)
  **Quinine & Septrin**                                                                                                                                                                                                                                                                                                                                                                                                                      
  Private For-Profit                               Private Hospital    TORORO     Eastern    Nurse    Enrolled Comprehensive     Female       27        8YR OLD GIRL REFERRED FROM A CLINIC AFTER RECEIVING IV QUININE & SEPTRIN DEVELOPED BLISTERS ALL-OVER THE BODY & DIED ON ADMISSION---SEVERE                                                                                                                                           BNF
  Private Not-for-Profit                           Private Hospital    TORORO     Eastern    Nurse    Enrolled Comprehensive     Female       30        5YR OLD GIRL FROM A CLINIC WHERE SHE WAS PUT ON IV QUININE & SEPTRIN. GOT BLISTERS ALL OVER THE BODY & DIED ON ADMISSION---SEVERE                                                                                                                                                    BNF
  Private For-Profit                               Private Hospital    TORORO     Eastern    Nurse    Nursing Assistant          Female       29        5YR OLD GIRL WAS REFERRED FROM A CLINIC AFTER TAKING IV QUININE & SEPTRIN WITH BLISTERS ALL-OVER THE BODY. SHE DIED ON ADMISSION---SEVERE                                                                                                                                            BNF
  **Coartem**                                                                                                                                                                                                                                                                                                                                                                                                                                
  Private Not-for-Profit                           Health Centre IV    KAMPALA    Central    Other                               Male         34        SWELLING OF FACE IN 16YR PATIENT AFTER SWALLOWING COARTEM (ORALLY)-MODERATE                                                                                                                                                                                                          [Drugs.com](http://Drugs.com)
  Private For-Profit                               Regional Referral   LIRA       Northern   Nurse    Registered Nurse           Female       27        26YR/MALE ON COARTEM ORAL ROUTE,RASH ON BOTH HANDS, ITCHING & SWELLING                                                                                                                                                                                                               [Drugs.com](http://Drugs.com)
  Public                                           Health Centre IV    JINJA      Eastern    Doctor                              Male         24        52YR OLD FEMALE ON COARTEM ORAL ROUTE DEVELOPED SORES ON THE WHOLE BODY                                                                                                                                                                                                              [Drugs.com](http://Drugs.com)
  **Mefloquine**                                                                                                                                                                                                                                                                                                                                                                                                                             
  Private Not-for-Profit                           Health Centre IV    MASINDI    Western    Doctor                              Male         62        62YR/FEMALE ON ORAL MEPHAQUINE GOT SEVERE HEADACHE WITH MENTAL CONFUSION & INSOMNIA                                                                                                                                                                                                  [Drugs.com](http://Drugs.com)
  **Fansidar**                                                                                                                                                                                                                                                                                                                                                                                                                               
  Private Not-for-Profit                           Health Centre IV    TORORO     Eastern    Other                               Male         24        36YR OLD ON ORAL FANSIDAR (SULPHADOXINE/PYRIMETHAMINE) DEVELOPED HYPERPIGMENTATION OF THE SKIN & THE THROAT---MILD                                                                                                                                                                   [Drugs.com](http://Drugs.com)
  **Diclofenac**                                                                                                                                                                                                                                                                                                                                                                                                                             
  Private Not-for-Profit                           Private Hospital    KAMPALA    Central    Doctor                              Male         28        ORAL DICLOFENAC 50MG, HAEMOPTYSIS AFTER 2 DAYS---WAS SEVERE[\*](#t005fn002){ref-type="table-fn"}                                                                                                                                                                                     Yiannakopoulou EC 2011, Van Renterghemet al 2012
  Private For-Profit                               Private Hospital    TORORO     Eastern    Nurse    Registered Comprehensive   Female       29        65YR/FEMALE PATIENT\'S BLOOD PRESSURE LOWERED FROM 105/60 TO 86/50 MMHG & STARTED SWEATING AT A TEMPERATURE OF 35.0 DEGREES CELSIUS DUE TO DYNAPAR (IV DICLOFENAC INFUSION)---MILD                                                                                                   [Drugs.com](http://Drugs.com)
  **NVP-based HAART Regimen**                                                                                                                                                                                                                                                                                                                                                                                                                
  Public                                           National Referral   KAMPALA    Central    Doctor                              Female       39        45YR PATIENT ON ORAL TDF/3TC/NVP GOT SEVERE ABDOMINAL PAIN WHICH WAS IN COLICKY FORM                                                                                                                                                                                                 [Drugs.com](http://Drugs.com): Abdominal pain rare for Tenofovir
  Public                                           National Referral   KAMPALA    Central    Doctor                              Male         29        ISS PATIENT WITH SKIN RASH,SCALING,ULCERATIONS FOR 2WKS THAT STARTED 1WK AFTER ART INITIATION OF COMBIVIR-NEVIRAPINE (AZT/3TC/NVP)                                                                                                                                                   BNF
  **Efavirenz**                                                                                                                                                                                                                                                                                                                                                                                                                              
  Public                                           District Hospital   BUIKWE     Central    Nurse    Registered Nurse           Female       25        MILD ADR.PATIENT ON ORAL EFV HAD GYNAECOMASTIA AND JERKS                                                                                                                                                                                                                             BNF
  **Ceftriaxone**                                                                                                                                                                                                                                                                                                                                                                                                                            
  Public                                           Private Hospital    KAMPALA    Central    Pharm                               Female       24        REACTION TO CEFTRIAXONE WITH MILD INFLAMATION &SWELLING AT POINT OF INJECTION[\*](#t005fn002){ref-type="table-fn"}                                                                                                                                                                   BNF
  **Gentamicin**                                                                                                                                                                                                                                                                                                                                                                                                                             
  Public                                           Regional Referral   KAMPALA    Central    Doctor                              Male         28        26YR ANAEMIC FEMALE WITH SEVERE PRE-ECLAMPSIA FINALLY DELIVERED & WAS MANAGED POST-OPERATIVELY WITH GENTAMICIN-SUSTAINED ACUTE RENAL FAILURE WITH ANAEMIA FOR 5 DAYS & OTHER COMPLICATIONS                                                                                           BNF
  **Ciprofloxacin**                                                                                                                                                                                                                                                                                                                                                                                                                          
  Private For-Profit                               District Hospital   MASINDI    Western    Other                               Male                   28YR/MALE---ALLERGIC REACTION TO ORAL CIPROFLOXACIN---SEVERE URTICARIA---SUBSTITUTED FOR CEPHALEXIN & CETIRIZINE[\*](#t005fn002){ref-type="table-fn"}                                                                                                                                BNF
  Public                                           Health Centre III   WAKISO     Central    Doctor                              Female       30        CHILD ON IV CIPROFLOXACIN GOT BODY ITCH, SWELLING AROUND THE FACE & AROUND SITE OF THE INJECTION                                                                                                                                                                                     BNF
  Public                                           National Referral   KAMPALA    Central    Nurse    Registered Nurse           Female       26        PATIENT WAS ON CIPRO AND GOT SWOLLEN HANDS                                                                                                                                                                                                                                           BNF
  **Metronidazole**                                                                                                                                                                                                                                                                                                                                                                                                                          
  Private For-Profit                               Other               MASAKA     Southern   Nurse    Enrolled Nurse             Female       28        23YR OLD,FLAGYL,ITCHING & NAUSEA,MILD                                                                                                                                                                                                                                                BNF
  **Omeprazole**                                                                                                                                                                                                                                                                                                                                                                                                                             
  Public                                           National Referral   KAMPALA    Central    Nurse    Registered Nurse Midwife   Female       31        SEVERE PALPITATIONS DUE TO OVER DOSE OF OMEPRAZOLE                                                                                                                                                                                                                                   [Drugs.com](http://Drugs.com)
  **Paracetamol**                                                                                                                                                                                                                                                                                                                                                                                                                            
  Private Not-for-Profit                           National Referral   GULU       Northern   Doctor                              Female       35        41YR/MALE GIVEN PANADOL (PARACETAMOL), STARTED SHAKING & SWEATING 10 MINUTES LATER.WAS PUT ON A DRIP AND HE BECAME FINE.                                                                                                                                                             [Drugs.com](http://Drugs.com): Database powered by Wolters Kluwer Health, American Society of Health- System Pharmacists, Cerner Multum and Thomson Reuters Micromedex. Not in BNF.
  Public                                           Regional Referral   LIRA       Northern   Doctor                              Female       40        10YR/MALE REACTED TO PANADOL (PARACETAMOL) WHEN TOOTH WAS REMOVED, BECAME DIZZY-MINOR                                                                                                                                                                                                Mescape---frequency not defined
  **Phenobarbitone**                                                                                                                                                                                                                                                                                                                                                                                                                         
  Public                                           District Hospital   TORORO     Eastern    Nurse    Registered Mental Health   Female       32        18YR/MALE MAN TAKING ORAL PHENORBABITONE GOT RASHES ALL OVER THE BODY SEVERE                                                                                                                                                                                                         BNF
  **Piperazine**                                                                                                                                                                                                                                                                                                                                                                                                                             
  Public                                           Pharmacy            MBRA       Southern   Other                               Male                   24YR/FEMALE DEVELOPED AN INFLAMATORY ITCHY RASH ALL-OVER AFTER TAKING ORAL PIPERAZINE,STOPPD IT AND PATIENT IMPROVED---MODERATE                                                                                                                                                      BNF

**KEY:** ADR = ADVERSE DRUG REACTION; ART = ANTIRETROVIRAL THERAPY; AZT = ZIDOVUDINE; BNF = BRITISH NATIONAL FORMULARY; EFV = EFAVIRENZ; FLAGYL = METRONIDAZOLE; HAART = HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; ISS = IMMUNOSUPRESSED SYNDROME; IV = INTRAVENOUS; MEPHAQUINE = MEFLOQUINE; NVP = NEVIRAPINE; SEPTRIN = COTRIMOXAZOLE; SJS = STEVENS-JOHNSON SYNDROME; TDF = TENOFOVIR; 3TC = LAMIVUDINE;

\* = CHECK APPENDIX S4 FOR TWO OR MORE DESCRIBED ADVERSE DRUG REACTIONS; PHARM = PHARMACIST/PHARMACY TECHNICIAN.

Additional ADR descriptions involving skin ulcerations, blistering, sloughing/peeling, and black skin patches; burnt face and lips; sore mucous membranes or general body sores; and death were linked to cotrimoxazole \[12 of 38 cases\] and nevirapine \[1 of 38 cases\] administration. Severe urticaria, swelling of the face, hands, and injection site were associated with ciprofloxacin use \[3 of 38 cases\]. Death, miscarriage, skin blistering and body itching were associated with quinine use \[8 of 38 cases\]. Severe palpitations due to overdose of omeprazole \[1 case\]; haemoptysis (coughing up of blood) after oral administration of diclofenac \[1 case\]; and mental confusion due to mefloquine \[1 case\] were also reported; for 11 others cases, see [Table 5](#pone.0123974.t005){ref-type="table"}.

Unanticipated suspected ADRs {#sec018}
----------------------------

Six unanticipated suspected ADRs (not backed by existing literature) were described: generalized body sores after oral coartem (artemether-lumefantrine); hypotension and sweating after intravenous diclofenac; reduced blood pressure and low pulse after chloramphenicol injection; severe burning sensation in the private parts immediately after intravenous hydrocortisone; irritability after intravenous quinine; and shaking and sweating for 10 minutes after receiving paracetamol, see [S4 Appendix](#pone.0123974.s004){ref-type="supplementary-material"}.

Summary of suspected ADRs {#sec019}
-------------------------

In summary, 106 serious, 51 rare, and six unanticipated past-month ADRs were described by 1,345 respondent HCPs, who, on average, saw 41 patients daily (SE = 1.3). Including overlaps between the patients seen, the reporting period accounts for over 1.5 million patient-days (1,345\*41\*28 = 1,544,060 patient-days). If our respondents can be considered representative, and for future planning, we estimate that, per 4-weeks, 100 Ugandan HCPs may encounter eight (8) serious, four (4) rare, and fewer than one (0.5) unanticipated suspected ADRs.

Discussion {#sec020}
==========

Ninety percent (241/268) of surveyed HCPs who suspected an ADR in the previous month described the most recent past-month suspected ADR they had encountered. Although the proportion of HCPs who provided these ADR description(s) was high, elsewhere we have reckoned\[[@pone.0123974.ref005]\] that only a small proportion (13%) of previous-month suspected ADRs that our surveyed Ugandan HCPs detected in routine clinical practice was formally reported. Moreover, the number of ADR reports (241 reports from 1,345 HCPs) in our study was higher than the Ugandan National Pharmacovigilance Centre's annual mean number of ADR reports (207 reports from 46,566 HCPs) over the previous six and a half years\[[@pone.0123974.ref005]\]. Our study, therefore, demonstrated a high level of motivation to describe the most recent previous-month suspected ADRs amongst the surveyed HCPs; however, the impetus for voluntary reporting of suspected ADRs in routine clinical practice is still very low\[[@pone.0123974.ref005]\].

Half of the ADR descriptions provided (124/241) were comprehensive. The extent of comprehensive ADR description is laudable given the fact that we elicited information on the most recent previous-month suspected ADR by recall and without prior sensitization of the HCPs about this survey. Half of the reports explicitly cited route of administration but route could nonetheless be inferred from the named drug in a further 26% (63/241) of descriptions. To eliminate errors in analysis of reported suspected ADRs, HCPs ought always to report drug route clearly.

Completeness and relevance are VigiBase database measures coined by the Uppsala Monitoring Centre (UMC) to assess the amount and quality of detail in Individual Case Safety Reports (ICSRs) received from National Pharmacovigilance Centres\[[@pone.0123974.ref009]\]. Completeness is quantitative and it measures to what level an ICSR is complete after NPC has liaised with the HCP-reporter, see [S2 Appendix](#pone.0123974.s002){ref-type="supplementary-material"}, while relevance is qualitative and can be used to assess causal relationships between a drug and an ADR\[[@pone.0123974.ref009]\]. The relevance algorithm, however, is still being developed\[[@pone.0123974.ref009]\]. Our findings could enhance the process of developing algorithms used to assess the level of detail and quality of information in ADR reports, such as need for explicit route of administration. It is the responsibility of individual countries to improve the quality of ADR reports that they receive from HCPs.

Comprehensive "free text" suspected ADR description provides additional detailed qualitative information that could enhance "completeness" and "relevance" assessment of ICSRs by NPCs, and generates stronger medication safety signals which, in turn, might promote proper characterization of reported suspected ADRs. More certainty about the nature of suspected ADRs and efficiency in taking appropriate measures to prevent these medication safety threats to patients is the result. Determining the characteristics of HCPs who are less likely to provide comprehensive ADR reports can help to identify HCPs to whom interventions aimed at improving the comprehensiveness (and ultimately overall quality) of ADR reporting can be targeted while at the same time utilizing the skills of the more comprehensive ADR reporters to strengthen/support improvements in the overall quality of suspected ADR reporting in Uganda.

Published literature which gives an in-depth account of the level of detail in ADR descriptions reported by HCPs in sub-Saharan Africa (SSA) was lacking. This study, therefore, provided empirical data on HCP-described ADRs in diverse health facilities in a Ugandan setting. The aim was to stimulate further research and intellectual discourse on comprehensiveness of ADR reporting in SSA in order to inspire similar, periodic but prospectively designed studies, to understand and improve the overall quality of ADR-reporting by HCPs in limited-resource settings where the use of technology-aided electronic ADR signal detection in daily clinical practice is not yet widely implemented. We assessed five higher-level descriptors provided in free-text recalled descriptions, but acknowledge that suspected ADR reports ought also to have relevant information to facilitate ADR causality assessment\[[@pone.0123974.ref010]\] and risk-benefit evaluation of medicines used in daily clinical practice\[[@pone.0123974.ref017]\]. For this reason, we recommend that a prospective version of our survey-approach to recording suspect ADRs be put in place by hospitals: for example, in two randomly selected months every year. Prospective recording during the survey months not only allows HCPs' multiple reports of the same suspected ADR to be identified but also allows contemporary consideration of causality and of the ward's medication-frequency for implicated drugs.

Working at private health facilities was associated with more comprehensive ADR descriptions. Thus, whereas past-year ADR reporting was lower in private-for-profit health facilities as compared with the public health sector\[[@pone.0123974.ref005]\], survey ADR descriptions from HCPs in private settings were three times more likely to be comprehensive. Any future interventions aimed at raising the ADR reporting rate by HCPs in both private and public health facilities should take into account both stimulation of, and the quality of, submitted ADR reports.

Healthcare professionals in regions other than in central Uganda had a higher likelihood to report comprehensive ADR descriptions. This finding might reflect the intensive NPC-led pharmacovigilance training focused on HCPs in regional referral hospitals when regional pharmacovigilance centres were first established in Uganda.

Healthcare professionals who were involved in the teaching of medical students were less likely to provide comprehensive ADR descriptions and yet it is these HCPs who bear the responsibility of introducing, to the medical students, the basic principles of pharmacovigilance during the formative years of the students' medical training. Targeted interventions to improve the comprehensiveness of ADR reports received from HCPs in teaching hospitals as well as lower level health facilities are essential to the strengthening of grassroots pharmacovigilance in Uganda. To stimulate more comprehensive ADR reporting, tables of serious and rare ADRs, such as those reported in this paper, should be provided both locally and nationally as feedback to HCPs. These tables group the received ADR reports meaningfully and indicate the rarity of the described ADR, where available, according to conventional references.

Lifetime encountering of a fatal ADR was not related to comprehensive ADR reporting. Thus, whereas occurrence of a fatal ADR might stimulate ADR reporting\[[@pone.0123974.ref005]\], it may not be an important factor in determining the comprehensiveness of reporting on suspected ADRs. Professional cadre, age of HCP, receipt of a previous-month patient ADR complaint, involvement in medical research, patient load, department, and knowing to whom to report ADRs were not statistically significantly associated with the reporting of comprehensive ADR descriptions among the surveyed HCPs.

The comparative advantage of post-marketing pharmacovigilance over randomized control trials (RCTs) is the ability to detect rare, serious, unanticipated, and/or delayed suspected ADRs that occur after a new drug product has been licensed for use on the open market. Moreover, RCTs are conducted in fewer subjects and in an experimental environment that may not adequately reflect the conditions of the "real word" healthcare setting\[[@pone.0123974.ref018], [@pone.0123974.ref019]\]. Spontaneous and voluntary ADR reporting systems provide an inexpensive post-marketing pharmacovigilance system that can be used to identify and prevent ADRs (e.g. rare and serious ones) and other drug-related problems.

Severity (grade or intensity) was not reported for half of the serious (incapacitating or life-threatening) ADRs suggesting that Ugandan HCPs rate seriousness higher than severity or that they do not take reporting of severity to be as important.

Miscarriage, post-injection paralysis, and child deaths were examples of serious ADRs associated with quinine use. Post-injection paralysis has previously been found to be associated with the bad clinical practice of inappropriate injection of quinine into the sciatic nerve by inadequately trained HCPs\[[@pone.0123974.ref020]\], which necessitated Uganda's policy change of the quinine injection site from the gluteus muscle to the thigh\[[@pone.0123974.ref021]\]. Adult doses of oral and intravenous quinine can be administered safely in pregnancy\[[@pone.0123974.ref015]\] but high doses may cause miscarriage\[[@pone.0123974.ref022]\].

Rare ADRs occur in \[[@pone.0123974.ref001]--[@pone.0123974.ref010]\] per 10,000 individuals (0.01% to 0.1%) and very rare ADRs occur in fewer than 1 in 10,000 (\< 0.01%) individuals receiving a specified medicine\[[@pone.0123974.ref014]\]. Two-thirds (65%, 95% CI: 33/51) of rare suspected ADRs were serious thus underlining the importance of pharmacovigilance in tracking medication safety since reported rare ADRs are usually serious (incapacitating or life-threatening)\[[@pone.0123974.ref017]\]. Stevens-Johnson syndrome (SJS), a rare but serious skin-associated ADR, was the most frequently reported, and it was mostly linked to the use of the antimicrobials (antibacterials and antiretrovirals), specifically nevirapine and cotrimoxazole. Similarly, antimicrobials were the most likely cause of SJS in a multicentre retrospective study conducted in India where nevirapine \[9 of 32 cases\] and cotrimoxazole \[7 of 32 cases\] also contributed most to the frequency of observed SJS\[[@pone.0123974.ref023]\]. The one case of diclofenac-associated haemoptysis described in this survey corroborates the findings of two recently documented case reports: one in Switzerland\[[@pone.0123974.ref024]\] and another in Belgium\[[@pone.0123974.ref025]\]. Rare and potentially fatal suspected ADRs are more likely to be identified after drugs have been licensed for use on the open market and voluntary ADR reporting by HCPs is a cornerstone of generating alerting adverse reaction signals\[[@pone.0123974.ref017]\].

One limitation to this study is that some suspected ADR(s) were described by more than one HCP(s)\[[@pone.0123974.ref005]\]. Due to differences in the level of detail provided in the various ADR descriptions, we were unable to establish the full extent of multiply described incidents, a challenge that may be encountered by any voluntary ADR reporting system but one that can be mitigated if ADRs are described comprehensively. A second limitation is recall bias owing to the use of self-report but we mitigated this challenge by restricting the recall period for the ADR description to the previous one month. A third limitation is that neither the reporters nor the lead author performed ADR causality assessment to confirm causal relationships between the suspected ADRs and the implicated drugs. Although the rare, serious or unanticipated ADRs reported in this paper should be interpreted cautiously, the study investigators cross-checked each suspected ADR against authoritative reference texts using the online British National Formulary as the main reference\[[@pone.0123974.ref015]\]. We also maintain that HCPs need only to suspect and subsequently to report suspected adverse reactions to pharmacovigilance (PV) units without the prior requirement for formal causality assessment. Thus, NPCs should have the skilled personnel to be able to perform ADR causality assessment. Moreover, it is in this voluntary system of ADR reporting that a number of ADRs relating to post-marketed drugs are first identified.

Our study has generated key positive insights into how comprehensive and how alerting are the suspected ADRs reported by surveyed Ugandan HCPs.

Conclusions {#sec021}
===========

Surveyed Ugandan HCPs who had suspected at least one ADR in the previous month competently provided comprehensive ADR descriptions: more, indeed, than are received per annum nationally. Properly analyzed, and with local feed-back, voluntary ADR reports by HCPs could be an essential alerting tool for identifying rare and serious suspected ADRs in Uganda.
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